Window-of-opportunity clinical trials platform for evaluation of novel treatment strategies in renal cell cancer.

Research summary

Any patient suspected of having surgically resectable clear cell renal cell carcinoma (ccRCC) (M0/M1) is suitable for screening for WIRE. The study will provide participants with exposure to novel agents as monotherapy and in combination during the period of time between the decision to undergo surgery and resection. This period of time is 4 weeks due to UK cancer targets, during which patients would otherwise remain untreated. The aim of WIRE is to determine if the novel agents will deliver their expected biological effect, as assessed by imaging (i.e. vascular permeability by a reduction in ktrans assessed by DCE MRI) or molecular analysis (e.g. activation of the immune system as measured by an increase in CD8 positive T-cells). Routinely in this setting, patients will attend clinic post-scan and/or biopsy, where a decision will be made to perform surgery to remove the tumour. Cancer targets dictate that this surgery should be performed within 28 days of listing for surgery. Unfortunately during this window, the patients routinely remain without 'active' treatment. The WIRE trial attempts to test a series of novel therapeutic strategies during this window for their anticipated biological effects, assessed by the use of imaging and blood tests. We would like to undertake this research because the results that we expect to see will hopefully benefit patients recruited and lead to future research which will benefit patients in the future.

Principal Investigator

Mr Mark Sullivan

Contact us

Email: crndirectdeliveryteam@ouh.nhs.uk

IRAS number

252392